【摘要】 目的探讨不同体重指数(BMI)2型糖尿病(T2DM)患者血清甘丙肽(GAL)水平及其与血糖、血脂等的关系。方法纳入T2DM患者(T2DM组)195例及正常对照者(NC组)50例,根据BMI将T2DM患者分为糖尿病正常体重组(DM-NW组)、糖尿病超重组(DM-OW组)和糖尿病肥胖组(DM-OB组),收集其一般资料并检测其血糖、血脂等生化指标,计算胰岛素抵抗指数(HOMA-IR)。采用酶联免疫吸附试验(ELISA)检测其血清GAL水平。采用多元线性回归分析GAL水平的影响因素。结果与NC组相比,T2DM组的GAL水平明显升高,且DM-NW组、DM-OW组、DM-OB组GAL水平依次升高(P<0.05)。相关性分析结果显示,血清GAL水平与糖尿病病程、甘油三酯(TG)、Ln(HOMA-IR)、糖化血红蛋白(HbAlc)、BMI均呈正相关,与Ln[空腹胰岛素(FINS)]呈负相关(P<0.05)。多元线性回归分析结果显示,BMI、糖尿病病程、TG、HbA1c、HOMA-IR均为血清GAL水平的独立影响因素(P<0.05)。结论GAL与糖、脂代谢及BMI有相关性,可能为超重/肥胖T2DM患者的治疗提供新靶点。更多还原

【Abstract】 Objective To investigate the levels of serum galanin(GAL) and its relationship with blood lipid and glucose related indexes in patients with type 2 diabetes mellitus(T2 DM) of different body mass indexes( BMI). Methods A total of 195 patients with T2 DM(T2 DM group) and 50 normal control subjects(NC group) were enrolled. T2 DM patients were divided into diabetes with normal weight group(DM-NW group),overweight diabetic group(DM-OW group) and obesity diabetic group(DM-OB group)according to BMI. General data of the subjects were collected, the biochemical indexes incuding blood glucose and lipid as well as GAL were detected, and insulin resistance index(HOMA-IR) was calculated.The level of serum GAL was detected by enzyme-linked immuno sorbent assay( ELISA). The related factors of GAL were analyzed by multiple linear regression analysis. Results Compared with NC group,the level of GAL in the T2 DM group was higher(P <0. 05). In DM-NW,DM-OW and DM-OB groups,the levels of GAL increased(P <0. 05). The correlation analysis showed that the level of serum GAL was positively correlated with the course of diabetes, triglyceride( TG), Ln( HOMA-IR), glycosylated hemoglobin( HbAlc), BMI, and negatively correlated with Ln [fasting insulin( FINS) ](P <0. 05).Multiple linear regression analysis showed that BMI,course of diabetes,TG,HbAlc and HOMA-IR were independently correlated with serum GAL level( P < 0. 05). Conclusion There is a certain correlation between GAL and glucose metabolism,lipid metabolism and BMI, which may provide a new therapeutic target for overweight and obese T2 DM patients.更多还原